McKesson Earnings Call Highlights Growth, Cash Power

McKesson Corporation ((MCK)) has held its Q4 earnings call. Read on for the main highlights of the call.

McKesson’s latest earnings call struck a confident tone, with management highlighting broad-based growth, expanding margins and strong cash generation across fiscal 2026. While they acknowledged pockets of volatility from GLP‑1 demand swings, branded price pressure and separation-related costs, executives stressed that strategic investments in oncology, biopharma services and supply chain upgrades are already paying off and underpinning long-term targets.

Strong Full-Year Financial Performance

McKesson delivered another year of double-digit growth, with fiscal 2026 revenue climbing 12% to $403.0 billion and adjusted operating profit rising 15% to $6.5 billion. Adjusted EPS increased 18% to $39.11, and excluding prior-year McKesson Ventures gains, management emphasized that underlying EPS growth was closer to 20%, underscoring the strength of the core operations.

Robust Quarterly Results

The fourth quarter capped the year on a solid note as revenue rose 6% to $96.3 billion and adjusted EPS advanced 16% to $11.69. Profitability was particularly strong, with gross profit up 14% to $3.9 billion and operating profit up 13% to $1.8 billion, signaling that McKesson is managing mix, costs and pricing effectively despite industry headwinds.

Cash Generation and Capital Returns

The company underscored its cash engine, citing fiscal 2026 operating cash flow of $6.2 billion and free cash flow of $5.4 billion. McKesson returned $5.1 billion to shareholders via buybacks and dividends, including a $2.25 billion accelerated repurchase in Q4, and secured Board approval for another $5.0 billion, bringing total repurchase capacity to roughly $7.7 billion.

Oncology & Multispecialty Momentum

Oncology and multispecialty operations were a standout, with Q4 revenue up 35% to $12.7 billion and operating profit up 53% to $385 million. The segment added more than 570 providers, its largest net increase since 2010, and acquisitions such as PRISM and Core Ventures materially boosted both revenue and profit growth, signaling durable momentum.

Biopharma Services Scale and Productivity Gains

McKesson’s biopharma services arm continued to scale, delivering record annual verifications and supporting a record 3.4 million patients across brand and specialty therapies. The company estimates it helped patients save about $10 billion on medicines and prevented roughly 12 million prescription abandonments, while each employee supported about 120 more patients than last year, highlighting productivity gains.

GLP-1 and Specialty Growth

The popular GLP‑1 class remains a major growth driver, with Q4 distribution revenue jumping 22% year over year to $14 billion and full-year GLP‑1 revenue up 27% to $53 billion. In North American Pharmaceutical, segment operating profit grew 11% to $980 million, with modest margin expansion, reflecting the benefits of scale in specialty drugs even as management watched category volatility closely.

Operational Modernization and Supply Chain Resiliency

Management highlighted ongoing investments in automation and AI as key to securing future efficiency and resilience in the distribution network. A new Montreal distribution center with advanced automation and AI-driven storage and retrieval, plus an AI-enabled planning system, is already driving working capital savings and helped McKesson navigate a major winter storm with minimal customer disruption.

Progress on Medical-Surgical Separation and Strategic Partnerships

The planned separation of the Medical‑Surgical business advanced, with McKesson completing key financing steps including a $1.0 billion term loan and a $1.0 billion revolver. The company also announced a $1.25 billion minority investment from Apollo for roughly a 13% stake in the new entity, valuing it around $13 billion and creating flexibility to recycle proceeds into share repurchases.

Branded Pricing Pressure and Revenue Drag

Despite strong overall growth, management noted that branded pharmaceutical price declines weighed on reported revenue, cutting year-over-year growth by about 3% in the quarter. Executives tied some of this pressure to recent policy-driven pricing changes but stressed that operating profit held up well, implying that McKesson is offsetting revenue drag through mix and efficiency.

GLP-1 Sequential Volatility

While GLP‑1 revenues surged year over year, the company acknowledged quarter-to-quarter swings in the category, noting a 4% sequential decline in Q4. Management framed this as a reminder that despite robust structural demand, GLP‑1 volumes can fluctuate with supply patterns and inventory adjustments, which may introduce forecasting noise for investors.

Medical-Surgical Segment Performance and Risks

The Medical‑Surgical Solutions segment posted modest top-line growth, with Q4 revenue up just 1% and operating profit down 5% to $271 million. Fiscal 2027 guidance for the unit points to only low single-digit revenue growth and flat-to-modest profit gains, and management flagged that the separation still depends on financing and regulatory approvals, adding execution risk.

GAAP and One-Time Items Affecting Comparability

Executives urged investors to look through several GAAP-only items in the quarter, including a $480 million gain on the Norway divestiture and noncash adjustments tied to redeemable noncontrolling interests. A $182 million LIFO credit also boosted reported results, and management emphasized that these factors distort year-over-year comparisons and should be stripped out to gauge underlying trends.

Rising Operating and Corporate Expenses

Operating expenses rose 14% in Q4 to $2.1 billion, reflecting elevated spending on oncology and multispecialty expansions as well as integration costs from recent deals. Corporate expenses climbed to $209 million, pressured by losses in the ventures portfolio and increased technology infrastructure investments, underscoring the cost side of McKesson’s growth strategy.

Guidance Shows Some Cash Flow and Interest Headwinds

The company flagged that fiscal 2027 free cash flow is expected to fall to $4.5–$4.9 billion, about 10–13% below fiscal 2026, as separation-related financing and timing effects weigh on cash. Interest expense is projected at $380–$420 million, reflecting incremental debt tied to the Medical‑Surgical separation, which will raise below-the-line costs even as operating earnings grow.

Quarter-to-Quarter Variability in Prescription Technology Solutions

Guidance for the Prescription Technology Solutions segment points to more modest revenue growth of 2.5–6.5% next year, with operating profit expected to grow a healthier 11–15%. Management cautioned that this 3PL-heavy business can be lumpy, with results moving around based on the timing of product launches, program ramps and utilization trends, which can obscure longer-term growth.

Execution and Integration Costs

Acquisitions like PRISM and Core Ventures are fueling top-line and profit expansion but are also driving higher near-term operating expenses and integration costs. Management also acknowledged non-operational adjustments and equity losses from its venture portfolio, which weighed on corporate results and serve as a reminder that deal execution and portfolio investments carry earnings volatility.

Forward-Looking Guidance and Long-Term Outlook

For fiscal 2027, McKesson guided adjusted EPS to $43.80–$44.60, representing 12–14% growth and potentially 14–16% when excluding Norway-related items, supported by 5–9% revenue and 8–12% operating profit growth. Segment guidance calls for mid-single-digit growth in North American Pharmaceutical, high-teens growth in Oncology & Multispecialty, and double-digit profit growth in Prescription Technology Solutions, alongside roughly $5 billion of planned share repurchases and reaffirmed long-term EPS targets.

McKesson’s earnings call ultimately painted the picture of a company leaning into high-growth niches while methodically reshaping its portfolio and infrastructure. Investors will need to monitor execution on the Medical‑Surgical separation, GLP‑1 volatility and rising corporate costs, but the combination of solid cash generation, disciplined capital returns and reaffirmed double-digit EPS ambitions leaves the long-term equity story intact and compelling for patient shareholders.